Deka BioSciences Revenue and Competitors

Rockville,

Location

$91M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Deka BioSciences's estimated annual revenue is currently $6.4M per year.(i)
  • Deka BioSciences's estimated revenue per employee is $155,000
  • Deka BioSciences's total funding is $91M.

Employee Data

  • Deka BioSciences has 41 Employees.(i)
  • Deka BioSciences grew their employee count by -16% last year.

Deka BioSciences's People

NameTitleEmail/Phone
1
President & CEOReveal Email/Phone
2
Co-founder & CBOReveal Email/Phone
3
VP, Developmental SciencesReveal Email/Phone
4
VP Technical OperationsReveal Email/Phone
5
VP, Clinical OperationsReveal Email/Phone
6
General CounselReveal Email/Phone
7
VP Clinical OperationsReveal Email/Phone
8
Clinical Project DirectorReveal Email/Phone
9
Associate DirectorReveal Email/Phone
10
Chief Operations OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Deka BioSciences?

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

keywords:N/A

$91M

Total Funding

41

Number of Employees

$6.4M

Revenue (est)

-16%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.9M41-9%N/A
#2
$4.9M41-5%N/A
#3
$8.9M415%N/A
#4
$9.5M413%N/A
#5
$8.4M41-11%$63.7M